Sugi Predict

Sugi Predict / Compounds / SCHEMBL79300

SCHEMBL79300

SCHEMBL79300

CC(C)(O)c1ccccc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 1/20 0.46
▸ CYP3A4 P08684 4/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.41
▸ TSHR P16473 4/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ HSD11B1 P28845 1/20 0.39
▸ CYP2C19 P33261 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CA2 P00918 2/20 0.37
▸ PIK3CA P42336 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ ADRA2B P18089 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29470925 1.00 PGR (0.46) PGRCYP3A4ALOX15SMN1; SMN2CASP1
SCHEMBL168119 0.85 CYP3A4 (0.43) PGRCYP3A4ALOX15SMN1; SMN2CASP1
SCHEMBL2790363 0.83 CYP3A4 (0.41) PGRCYP3A4ALOX15SMN1; SMN2CASP1
SCHEMBL2059781 0.81 ALDH1A1 (0.50) PGRCYP3A4ALOX15ALDH1A1TSHR
SCHEMBL29506834 0.81 ALDH1A1 (0.50) PGRCYP3A4ALOX15ALDH1A1TSHR
Methyl Alcohol SCHEMBL27473713 0.80 ALDH1A1 (0.52) CYP3A4ALOX15SMN1; SMN2CASP1CASP7
SCHEMBL2443511 0.79 ALDH1A1 (0.38) PGRCYP3A4ALOX15SMN1; SMN2CASP1
SCHEMBL895143 0.79 CYP3A4 (0.47) CYP3A4ALOX15SMN1; SMN2CASP1CASP7
SCHEMBL2202080 0.79 CYP3A4 (0.47) CYP3A4ALOX15SMN1; SMN2CASP1CASP7
SCHEMBL70170 0.79 TSHR (0.50) CYP3A4ALOX15SMN1; SMN2CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12610732-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2026-04-21 — — US disclosed
US-12497420-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-12-16 — — US disclosed
EP-4358685-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2025-12-03 — — EP disclosed
EP-4650415-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Universal Display Corporation (US) 2025-11-19 — — EP disclosed
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 — — US disclosed
EP-4380560-A1 LPAR1 ANTAGONISTS AND USES THEREOF Contineum Therapeutics, Inc. (US) 2024-06-12 — — EP disclosed
CN-118043041-A LPAR1 antagonists and uses thereof 康蒂内乌姆医疗公司 2024-05-14 — — CN disclosed
EP-4358685-A2 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Universal Display Corporation (US) 2024-04-24 — — EP disclosed
CN-113896744-B Selective EGFR inhibitor 成都先导药物开发股份有限公司 2024-04-16 — — CN disclosed
EP-3978583-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2024-04-10 — — EP disclosed
US-5541299-A Process for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1996-07-30 — — US disclosed
EP-0714299-A4 — — 1996-07-10 — — EP disclosed
EP-0714299-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-06-05 — — EP disclosed
US-5502171-A Process for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1996-03-26 — — US disclosed
EP-0446731-B1 Process for the manufacture of azo dyes BAYER AG (DE) 1995-05-03 — — EP disclosed
WO-1995002405-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 — — WO disclosed
EP-0446731-A2 Process for the manufacture of azo dyes BAYER AG (DE) 1991-09-18 — — EP disclosed
US-4831027-A USEFUL IN TREATMENT OF CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1989-05-16 — — US disclosed
EP-0263352-A1 Imidazo-benzoxazinones, their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1988-04-13 — — EP disclosed
US-4030906-A Herbicidal N-haloacetyl-1,2-dihydro-4H-3,1-benzoxazine CHEVRON RESEARCH COMPANY (US) 1977-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 PGR 1024/4885CYP3A4 4412/4885ALOX15 460/4885
US-12610732-B2 Organic electroluminescent materials and devices ICOSLG, SSB, SART3 PGR 667/4885CYP3A4 1908/4885ALOX15 3117/4885
US-12497420-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, OR10J3 PGR 3882/4885CYP3A4 492/4885ALOX15 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.